« Return to News | Awards & Advancement

Celerion receives ANVISA certification

Friday, June 10, 2011 11:33 AM

Lincoln, Neb.-based Celerion, a provider of early-stage drug development solutions, has announced that its clinical research operations in Belfast, Northern Ireland, and its clinical research and bioanalytical services operations in Lincoln, Neb., have been certified by the Brazilian National Health Surveillance Agency (Agência Nacional de Vigilância Sanitária – ANVISA). 

ANVISA provides regulatory approval for drugs and other products seeking to enter the large and growing Brazilian market.  ANVISA-certified service providers are qualified to help clients clear a key hurdle to access one of the fastest-growing major pharmaceutical markets in the world. 

“The approval of ANVISA continues to demonstrate the high-quality work done at Celerion,” said Susan Thornton, president and CEO.  “By earning ANVISA certification to conduct early clinical studies and bioanalytical research for compounds destined for Brazil, Celerion is now able to better serve our clients’ growing needs in this high-growth, emerging market.”

In addition to ANVISA certification, Celerion’s Belfast facility also has been certified by the U.K.’s Medicines and Healthcare products Regulatory Agency (MHRA). The facility has received both standard and supplementary accreditation from the MHRA, which certifies that the general standards for study participant safety and access to emergency medical response have been met.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.